Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ashley Trood

Physician Assistant Wichita, KS Physician Assistant

NPI 1285379164 CMS profile 11389551

9300 E 29Th St N Ste 204, Wichita, KS 67226

Open in the dashboard

General payments

$7,418

456 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Trood of Wichita, KS is reported in the CMS Open Payments database as having received $7,418 across 456 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,608 188
2024 General $2,076 125
2023 General $2,035 109
2022 General $699 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Trood
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Trood were reported at $2,608. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Trood Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $699 $155 $48–$522 $149
2023 $2,035 $167 $52–$557 $160
2024 $2,076 $178 $55–$600 $164
2025 $2,608 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Lilly USA, LLC $1,317 62 payments
  2. Novo Nordisk Inc $873 55 payments
  3. Dexcom, Inc. $728 51 payments
  4. Amgen Inc. $711 34 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $570 40 payments
  6. Recordati_Rare_Diseases_Inc. $397 18 payments
  7. Corcept Therapeutics $348 28 payments
  8. Insulet Corporation $330 46 payments
  9. Xeris Pharmaceuticals, Inc. $274 19 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $263 15 payments
  11. Other $1,608 88 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,393 455 payments
  2. Education $25 1 payment
Products named General payments · program years 2022–2025
  1. MOUNJARO $970 44 payments
  2. Dexcom G6 Transmitter $728 51 payments
  3. Kerendia $570 40 payments
  4. EVENITY $527 22 payments
  5. ZEPBOUND $493 25 payments
  6. Ozempic $451 30 payments
  7. RYBELSUS $406 25 payments
  8. ISTURISA $397 18 payments
  9. Korlym $348 28 payments
  10. Omnipod $330 46 payments
  11. Other $4,237 240 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,611

Median for Physician Assistant: 241

Drug cost

$1,035,786

Median for Physician Assistant: $4,110

Branded share of claims

59.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 311 $330,514
Jardiance Empagliflozin Brand 196 $204,680
Trulicity Dulaglutide Brand 121 $115,248
Mounjaro Tirzepatide Brand 87 $92,442
Farxiga Dapagliflozin Propanediol Brand 27 $37,250
Tresiba Flextouch U-200 Insulin Degludec Brand 36 $36,939
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 26 $35,731
Januvia Sitagliptin Phosphate Brand 35 $30,327
Prolia Denosumab Brand 15 $25,688
Tresiba Flextouch U-100 Insulin Degludec Brand 49 $23,588

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$63,137

Medicare's payments for the services billed

Medicare patients

395

Average age 71

Services billed

1,980

267 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 47%
Arthritis 43%
Ischemic heart disease 30%
Chronic kidney disease 26%
Osteoporosis 25%
Depression 22%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $266
$266 87 —
ZEPBOUND
  • Lilly USA, LLC $186
$186 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $177
$177 — —
Korlym
  • Corcept Therapeutics $175
$175 — —
ISTURISA
  • RECORDATI_RARE_DISEASES_INC. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

456 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record